a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare ...

The study, “Melanin concentrating hormone projections to the nucleus accumbens enhance the reward value of food consumption and do not induce feeding or REM sleep,” was authored by Katherine L ...

The melanin-concentrating hormone (MCH) is a neuropeptide (i.e., a compound that transmits information in the brain) produced by neurons in a region known as the lateral hypothalamic area (LHA).

In mouse models of ALS, the approved drug suvorexant and melanin-concentrating hormone were both able to decrease time awake and increase REM sleep. Suvorexant was also able to normalize non-REM ...

This receptor sits on the cell surface, and if it becomes activated by circulating hormones called melanocortins, it causes the melanocyte to switch from generating yellow/red melanin pigment to ...

That was intriguing, since the melanocytes (the cells that produce melanin) don’t have traditional hormone receptors. When the researchers took a closer look at the molecular pathways ...